This study assesses the cost-utility of OPAT compared to Inpatient Parenteral Antimicrobial Therapy (IPAT) from the perspective of a public university hospital and the Brazilian National Health System (SUS)” Psaltikidis et al (2018).
BACKGROUND: Outpatient Parenteral Antimicrobial Therapy (OPAT) has been used for decades in different countries to reduce hospitalization rates, with favorable clinical and economic outcomes. This study assesses the cost-utility of OPAT compared to Inpatient Parenteral Antimicrobial Therapy (IPAT) from the perspective of a public university hospital and the Brazilian National Health System (SUS).
METHODS: Prospective study with adult patients undergoing OPAT at an infusion center, compared to IPAT. Clinical outcomes and Quality-Adjusted Life Year (QALY) were assessed, as well as a micro-costing. Cost-utility analysis from the hospital and SUS perspectives was conducted by mean of a decision tree, within a 30-day horizon time.
RESULTS: Forty cases of OPAT (1,112 days) were included and monitored, with a favorable outcome in 97.50%. OPAT compared to IPAT generated overall savings of 31.86% from the hospital perspective and 26.53% for the SUS. The intervention reduced costs, with an Incremental Cost-Utility Ratio (ICUR) of -44,395.68/QALY for the hospital and -48,466.70/QALY for the SUS, with better cost-utility for treatment times greater than 14 days. Sensitivity analysis confirmed the stability of the model.
CONCLUSION: Our economic assessment demonstrated that, in the Brazilian context, OPAT is a cost-saving strategy both for hospitals and the SUS.
You may also be interested in…
Psaltikidis, E.M., Silva, E.N.D., Moretti, M.L., Trabasso, P., Stucchi, R.S.B., Aoki, F.H., Cardoso, L.G.O., Höfling, C.C., Bachur, L.F., Ponchet, D.D.F., Colombrini, M.R.C., Tozzi, C.S., Ramos, R.F., Costa, S.M.Q. and Resende, M.R. (2018) Cost-utility analysis of outpatient parenteral antimicrobial therapy (OPAT) in the Brazilian national health system. Expert Review of Pharmacoeconomics & Outcomes Research. October 26th. .